STT3A encodes the catalytic subunit of the oligosaccharyltransferase complex. A congenital disorder of glycosylation caused by mutations in STT3A has only been reported in one family to date, associated with a Type I congenital disorder of glycosylation pattern of transferrin glycoforms. The authors describe a further 5 related individuals with a likely pathogenic variant in STT3A, 2 of whom also had variants in TUSC3. Common phenotypic features in all symptomatic individuals include developmental delay, intellectual disability, with absent speech and seizures. Two individuals also developed episodic hypothermia and altered consciousness. The family were investigated by autozygosity mapping, which revealed both a homozygous region containing STT3A and, in addition, a homozygous deletion of TUSC3 in one child. A likely pathogenic variant in STT3A was confirmed on Sanger sequencing of all affected individuals: the authors discuss the molecular findings in detail and further delineate the clinical phenotype of this rare disorder.
1
The oligosaccharyltransferase complex is involved in the transfer of glycan chains to proteins in the endoplasmic reticulum. Oligosaccharyltransferase is composed of 7 or 8 subunits, of which mutations in 4 (TUSC3, MAGT1, DDOST, STT3) have been reported to cause congenital disorders of glycosylation, though only 2 (DDOST, STT3) are associated with abnormal glycosylation of transferrin. 2 The STT3 subunit is the catalytic subunit of oligosaccharyltransferase.
In mammalian cells, 2 distinct isoforms of the oligosaccharyltransferase complex are expressed, consisting of either the STT3A or STT3B subunits and shared accessory subunits. 3 The 2 alternate proteins have partially overlapping functions:
STT3A mediates cotranslational glycosylation of nascent polypeptide chains, while STT3B is responsible for posttranslational glycosylation of acceptor sites that have skipped glycosylation by the STT3A complex. 4, 5 Congenital disorder of glycosylation caused by mutations in STT3A, termed STT3A-CDG in current nomenclature, has to date been reported in only one family of Pakistani origin where 2 affected siblings presented with microcephaly, developmental delay, failure to thrive, seizures, and hypotonia. 2 The more severely affected brother also had problems with visual tracking and was reported to have cerebellar atrophy. The parents were consanguineous. A homozygous mutation c.1877C>T was identified in STT3A in this patient. The authors also described another individual in the same report with congenital disorder of glycosylation caused by mutations in STT3B.
Here the authors describe 5 individuals with congenital disorder of glycosylation caused by the identical variant in STT3A, 2 of whom coincidentally also carry a deletion of TUSC3, a gene encoding another subunit of oligosaccharyltransferase. Written informed consent was obtained from the families of all individuals for being included in the study.
Family History
The pedigree of the family is shown in Figure 1 . The authors investigated 2 male siblings (Patients IV-1 and IV-2) from a multiply consanguineous family of Pakistani origin because of developmental delay and feeding problems. The sister of the 2 boys (IV-3) has much less severe developmental delay but significant microcephaly (occipitofrontal circumference < 0.4th percentile). The youngest sibling (IV-4) was investigated at birth due to the diagnosis being known in his brothers. At one month of age he is so far asymptomatic with no abnormal neurological findings or microcephaly (occipitofrontal circumference on 25th percentile). The father of these 4 children had 2 siblings who died at an early age and were said to have problems similar to the eldest child. The mother has 2 brothers with severe learning difficulties, one of whom has epilepsy. They were not available for examination. Three maternal cousins (Patients III-7, III-8, and III-9) also presented with severe developmental delay, absent speech, and seizures. Two of the 3 had microcephaly.
Clinical Reports
The eldest sibling from Family 1 (Patient IV-1) was born at full term by Caesarean section due to breech presentation. Birth weight was 2.79 kg (9th percentile) and birth occipitofrontal circumference was 32 cm (2nd percentile). There were parental concerns about abnormal visual behavior by 4-6 weeks of age, and severe vomiting from 8 weeks. He presented to his local pediatrician at 11 weeks of age, by which time global developmental delay was apparent. He had significant head lag, truncal hypotonia, no social smile, severe visual impairment with roving eye movements and optic atrophy on fundoscopy. Newborn hearing screening assessments were satisfactory but subsequently there were concerns about hearing impairment; though parents felt that he was able to respond to voices of family members, no definite responses to sounds were observed in clinic. There were no dysmorphic features but he was severely microcephalic (below 0.4th percentile). No abnormality was seen on brain computed tomography (CT) performed at 4 months of age. By 5 months of age he had developed seizures, predominantly myoclonic jerks but with occasional generalized tonic-clonic seizures. At this stage, electroencephalogram (EEG) showed epileptiform activity in both temporal regions, predominantly over the right temporal region but occasionally in a more generalized distribution. By 2 years, the EEG showed a more generalized burst suppression pattern. Seizures were extremely difficult to control despite therapy with leviteracetam and phenobarbital. He continued to have 2 to 3 clusters of myoclonic jerks daily, often following waking. By 6 months of age he had developed spasticity of the lower limbs and this pattern of motor disability persisted. He has never been able to sit without support. Vomiting continued to be a major problem and he required complete gastro-oesophageal dissociation at 18 months and gastrostomy feeding. Oral secretions were problematic and were managed with hyoscine patches and glycopyrronium. There was no evidence of liver involvement and liver function tests were consistently normal.
From 4 years of age he developed episodes of reduced consciousness and hypothermia. At these times he appeared to be very deeply asleep and not rousable, with reduced respiratory rate and temperature dropping to 34-35 C ( Figure 2 ). These episodes could last for up to 2 days, during which time urine output was decreased. A cluster of seizures often followed waking from these episodes. Plasma thyroid stimulating hormone and free thyroxine were normal. He developed osteopenia and recurrent fractures. At 11 years of age he remained nonambulatory, requiring a customized wheelchair and gastrostomy feeding, with occasional myoclonic jerks and temperature variability; his weight was 40 kg (75th percentile), height was on the 25th percentile and occipitofrontal circumference was 49.1 cm (well below the 0.4th percentile). He died aged 12 years.
The younger brother of IV-1, IV-2 was born at full term by elective Caesarean section with a birth weight of 2.26 kg (<0.4th percentile). Delayed gross and fine motor development was apparent by 8 months. In contrast to his brother, there were no concerns regarding visual development or hearing, and there was no microcephaly, his occipitofrontal circumference being 41.5 cm (25th percentile) at the age of 5 months. At 15 months of age, he had a series of generalized tonic-clonic convulsions and was commenced on sodium valproate. Sleep deprived EEG demonstrated frequent bursts of spike and wave in a generalized pattern, consistent with generalized epilepsy. Though he did not have further generalized tonic-clonic convulsions, he continued to have frequent seizures of multiple types, including eye rolling, myoclonic jerks of the right arm and leg during sleep, and arm stiffening. These were treated with sodium valproate and lamotrigine, though he continued to have around 2 clusters of seizures per day. Feeding was difficult, necessitating gastrostomy insertion at the age of 2 years. At 3 years he had several episodes of mild hypoglycemia with inappropriately raised insulin levels. He was commenced on diazoxide, though this was discontinued after one year and monitoring of glucose levels was satisfactory. At 4 years he developed recurrent epistaxis and was found to have mildly abnormal coagulation, with a slightly prolonged prothrombin time (12.6 seconds) and normal activated partial thromboplastin time. The episodic epistaxis resolved spontaneously and no further intervention was considered necessary. Liver transaminases were normal.
From 4 years of age he began to have episodes of deep sleep, particularly after feeds, with the associated symptoms, such as cold extremities, also seen in his brother. These episodes occurred at any time of day and he would be unrousable for 3-4 hours. A 24-hour EEG showed no epileptiform activity. Thyroid function tests were normal. He continues to have infrequent seizures and episodes of deep sleep at 6 years of age. He has made some developmental progress and is able to reach a sitting position without support, though development remains globally delayed. Currently his weight is 24.5 kg (>75th percentile), height is 112 cm (9th percentile) and occipitofrontal circumference lies between 0.4th and 2nd percentiles.
The third affected individual, III-7, is a first cousin of the mother of individuals IV-1 and IV-2. She was born at full term by normal delivery following an uncomplicated pregnancy. Birth weight was 2.5 kg (2nd percentile). Developmental delay was apparent by 5 months of age. She developed generalized tonic-clonic seizures at 10 months of age and her EEG showed widespread bursts of bilateral sharp wave activity, consistent with generalized epilepsy. Seizures were controlled by sodium valproate. There were no concerns about hearing or visual impairment and she was not dysmorphic. Urine amino and organic acids and mucopolysaccharides, thyroid and liver function and a lysosomal enzyme screen were normal, as was CT brain at the age of 5 years. By 10 years of age she was making very slow developmental progress, still unable to walk, with increased muscle tone and limb contractures. She was also noted to have unusual stereotypic movements including some hand-wringing, rocking and head-banging. By 17 years of age she was losing weight due to very poor appetite and required gastrostomy insertion. She has never achieved independent ambulation but was able to walk with assistance and she had developed sleep disturbance. When last reviewed at 25 years, she had developed spasticity in the limbs and a kyphotic posture. She was less mobile and had a very poor sleep pattern and challenging behavior. She is microcephalic with occipitofrontal circumference below the 0.4th percentile.
The younger sister of III-7, III-8 was born at term and developed seizures at the age of 4 days associated with hypocalcaemia, thought to be secondary to maternal vitamin D deficiency. She went on to have severe developmental delay and persisting seizures, with a normal CT brain scan and normal routine investigations including liver function tests. By 5 years she was noted to have rocking movements similar to her sister. She also startled very easily. Her seizures were initially controlled with sodium valproate and lamotrigine but by the age of 15 years, she was able to stop anticonvulsants. There were no concerns about her hearing or vision and she has good comprehension but no expressive language. She began to walk with support at 3 years of age but had truncal ataxia and an unsteady gait. By age 3 years, she had limb hypertonia and walked with flexion at the hips. At age 20 years, she remains able to walk and does not have feeding problems but, like her sister, has developed sleep disturbance. She is overweight and has developed some dark pigmentation on her skin, considered to be acanthosis nigricans. Height is 149 cm (2nd percentile), weight 72 kg (>91st percentile) and occipitofrontal circumference lies on the 10th percentile.
The youngest sister, III-9 was born at term following an uncomplicated pregnancy. Her birth weight was 3.15 kg (25th percentile) and her initial head size lay on the 10th percentile. She developed seizures at 9 months of age, when she was also noted to have delayed gross and fine motor development, extensor hypertonia of the trunk and lower limbs and flexor hypertonia of the upper limbs. She developed body rocking movements similar to her sisters. She was not dysmorphic. A CT brain scan was normal. From 18 months of age, she has had severe problems with self-injurious behavior. Seizures were managed with carbamazepine, later changed to valproate.
Developmental progress was slow and though she is able to walk, at 17 years of age she is still dependent on her carers for all aspects of self-care, including feeding, dressing and bathing. Her weight lies on the 25th percentile but she is now microcephalic with an occipitofrontal circumference of 50.7 cm (<0.4th percentile).
The clinical features of all affected individuals are summarized in Table 1 and compared to the patient previously reported in the literature.
Further Investigations
A glycosylation disorder was suspected in the affected family members and iso-electric focusing of serum transferrin was carried out on IV-1, IV-2, III-7, and III-9 according to standard methods. 6 A satisfactory blood sample could not be obtained from III-8.
In view of the suspicion of an autosomal recessive disorder in the family, autozygosity studies were undertaken on the 3 affected siblings III-7, III-8, and III-9. Genome-Wide SNP microarray analysis using the Affymetrix Genome-Wide SNP6.0 microarray was carried out for the 3 affected siblings and genotypes were generated using the Birdseed v2 algorithm with a confidence threshold of 0.01 within the Affymetrix Genotyping console. Autozygosity analysis was carried out using AutoSNPa (http:// dna.leeds.ac.uk/autosnpa/) 7 to determine regions of autozygosity > 2 Mb. Copy number data were generated using the SNP 6.0 CN/LOH Algorithm within the Affymetrix Genotyping console v4.2 and visualized using Chromosome Analysis suite v2.1. All coordinates given are based on hg19. Candidate regions of interest were reviewed for potential disease-causing genes and STT3A was identified as one of these. Sanger sequencing of STT3A was subsequently undertaken in the affected individuals.
Results
In IV-1 initial results of transferrin isoelectric focusing were abnormal, but without a typical Type I or II congenital disorder of glycosylation pattern. Repeat analysis at 18 months showed an abnormal pattern of transferrin glycoforms consistent with Type I congenital disorder of glycosylation. Phosphomannomutase and phosphomannose isomerase enzyme activities were normal. In IV-2, analysis of transferrin glycoforms in the early neonatal period was normal, but repeat analysis at 1 month of age demonstrated a Type I congenital disorder of glycosylation pattern. Phosphomannomutase and phosphomannose isomerase enzyme activities were normal. In III-7, transferrin isoelectric focussing performed at 10 years of age was normal. Transferrin glycoforms in case III-9 showed a Type I congenital disorder of glycosylation pattern. It has not been possible to obtain a sample for testing from III-8.
On Sanger sequencing of STT3A, all 5 affected individuals, as well as the currently asymptomatic individual (IV-4), were found to have a homozygous change in STT3A c.1877T>C, p.(Val626Ala). This is the same variant as that reported in the family studied by Shrimal et al.
Analysis of the SNP array results undertaken for autozygosity studies revealed that IV-1 carried a 464 KB homozygous deletion of 8p22, with coordinates 8: (15,498,361-15,842,386 ). This results in partial nullisomy of the TUSC3 gene. This may explain the severity of his overall phenotype. This same deletion was carried in the heterozygous state only in IV-2, but in the homozygous state in the sister IV-3, explaining her phenotype of milder developmental delay and microcephaly. The deletion was not found in the currently asymptomatic individual IV-4.
Discussion
This is the second reported family with STT3A-CDG. The individuals described here share a number of clinical features with the only previously published report of an individual with STT3A-CDG 2 (Table 1) but have, in addition, other distinctive phenotypic features. In family 1, both affected males have prolonged episodes of altered consciousness and hypothermia. Perinatal hypothermia is a recognised feature of a number of inborn errors of metabolism (organic acidaemias, Menkes disease, pyruvate carboxylase deficiency) and lethargy and hypothermia shortly after birth has been reported in PMM2-CDG. 8 However, episodic lethargy and hypothermia in older children has not been reported as a feature of congenital disorder of glycosylation. These episodes suggest hypothalamic dysfunction with a disturbance of central thermoregulation, though spontaneous episodes of hypothermia with somnolence has been described in otherwise well children without evidence of hypothalamic dysfunction. 9 Hyperinsulinaemia has been postulated as the mechanism for spontaneous hypothermia in one case report 10 and patient IV-2 initially had evidence of hyperinsulinism but this had resolved before the onset of episodes of lethargy and hypothermia.
The 3 affected sisters all had stereotypic hand movements, raising the possibility of Rett syndrome. Later, repetitive rocking movements developed. They had a disordered sleep pattern and challenging and self-injurious behavior, which became the major management problem. Not all of the affected individuals in this reported family were microcephalic, demonstrating that this is not a universal feature of the condition.
The clinical picture in the elder sibling from Family 1 is likely to have been influenced by the fact that he also carries a homozygous deletion encompassing part of the TUSC3 gene at 8p22. This could explain why his phenotype has been so severe compared to the other affected individuals with the STT3A defect. Abnormalities of TUSC3 have been reported as a cause of autosomal recessive nonsyndromic intellectual disability, 11 the phenotype seen in IV-3, the sister of the affected boys. Unlike the STT3A defect, loss of function of TUSC3 does not result in hypoglycosylation of transferrin and it is hypothesized that the role of this subunit may be to ensure the glycosylation of a subset of proteins required for normal brain development. 12 The episodes of periodic lethargy and hypothermia are unlikely to be primarily due to the TUSC3 defect as they were observed in IV-2 who carries the deletion in the heterozygous state only, but not observed in the sister IV-3 who carries a homozygous deletion or in any previously reported patients. The occurrence of 2 different glycosylation disorders in the same family is coincidental but serves to remind us of the increasing number of glycosylation disorders now known to contribute to intellectual disability. Though to the authors' knowledge, 2 glycosylation disorders within the same family has not been reported previously, many children with developmental disorders have composite phenotypes resulting from mutations in 2 or more genes. 13 In summary, the authors report 5 individuals with STT3A-CDG to help delineate the phenotype. The authors highlight periodic lethargy and hypothermia, stereotypic behaviors and sleep disorder as possible distinctive features which might alert one to the diagnosis, especially in families of Pakistani origin. The STT3A variant identified in this family, c.1877C>T is identical to that described in the first family by Shrimal et al and may be a founder mutation in the Pakistani population.
